Horizon Kinetics’s Madrigal Pharmaceuticals MDGL Stock Holding History

Horizon Kinetics’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-514	Closed	-$5K	–	514
2016 Q2	$5K	Hold	514	–	–	﹤0.01%	520
2016 Q1	$4K	Hold	514	–	–	﹤0.01%	528
2015 Q4	$6K	Hold	514	–	–	﹤0.01%	507
2015 Q3	$31K	Buy	514 +57	+12%	+$4.11K	﹤0.01%	499
2015 Q2	$36K	Hold	457	–	–	﹤0.01%	515
2015 Q1	$31K	Buy	457 +143	+46%	+$12.3K	﹤0.01%	517
2014 Q4	$29K	Hold	314	–	–	﹤0.01%	517
2014 Q3	$33K	Hold	314	–	–	﹤0.01%	519
2014 Q2	$45K	Hold	314	–	–	﹤0.01%	528
2014 Q1	$47K	Buy	+314	New	+$61.8K	﹤0.01%	531

Other funds holding MDGL

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Horizon Kinetics's MDGL Position: Q3 2016 in Review

Horizon Kinetics sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2016, closing a stake of 514 shares — an estimated $5K sold.

Horizon Kinetics first reported a position in MDGL in Q1 2014 and held it in 10 quarters. The position peaked at $47K in Q1 2014. 31 funds tracked by Wall St. Rank hold MDGL as of Q3 2016.

Horizon Kinetics reported no remaining Madrigal Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Horizon Kinetics sold 514 Madrigal Pharmaceuticals shares in Q3 2016, an estimated $5K.
Horizon Kinetics first reported a position in Madrigal Pharmaceuticals in Q1 2014 and held it in 10 quarters.
Horizon Kinetics's Madrigal Pharmaceuticals position peaked at $47K in Q1 2014.
31 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2016.

Based on Horizon Kinetics's 13F filing for Q3 2016, filed 14 Nov 2016.